Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 3, 2008, Pages 543-552

  Chan, Simon K ^a,b   Griffith, Obi L ^a,b   Tai, Isabella T ^a,b   Jones, Steven J M ^a,b  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; CARBONATE DEHYDRATASE II; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CDC28 PROTEIN KINASE REGULATORY 2; CELL DIVISION CYCLE 25 HOMOLOGUE B; COLLAGEN TYPE 1 ALPHA2; CXCL1 CHEMOKINE; GROWTH DIFFERENTIATION FACTOR 15; HIGH MOBILITY GROUP BOX 1; IFN INDUCED TRANSMEMBRANE PROTEIN 1; IFN INDUCED TRANSMEMBRANE PROTEIN 2; MYC PROTEIN; ONCOPROTEIN; OSTEONECTIN; PROTEIN CDH3; PROTEIN CDK10; PROTEIN COL3A1; PROTEIN COL4A1; PROTEIN CSE1L; PROTEIN FCGBP; PROTEIN HNRPA1; PROTEIN HSD11B2; PROTEIN INHBA; PROTEIN MALL; PROTEIN SLC12A2; PROTEIN SLC26A2; PROTEIN TOP2A; PROTEIN UBE2C; STROMELYSIN 3; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ARTICLE; COLORECTAL CANCER; DOWN REGULATION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GENE EXPRESSION; HUMAN; PRIORITY JOURNAL; THYROID CANCER; UPREGULATION;

COLORECTAL NEOPLASMS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 41549166455     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-2615     Document Type: Article

References (71)

1. Shih W, Chetty R, Tsao MS. Expression profiling by microarrays in colorectal cancer [review]. Oncol Rep 2005;13:517-24.
2. Canadian Cancer Society: colorectal cancer stats. 4/07 update. Available from: http://www.cancer.ca/ccs/internet/standard/0,2283,3172_14447__langId-en, 00.html.
3. Srivastava S, Verma M, Henson DE. Biomarkers for early detection of colon cancer. Clin Cancer Res 2001;7:1118-26.
4. Wang Y, Jatkoe T, Zhang Y, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004;22:1564-71.
5. Kim J, Takeuchi H, Lam ST, et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 2005;23:2744-53.
6. Habermann JK, Paulsen U, Roblick UJ, et al. Stage-specific alterations of the genome, transcriptome, and proteome during colorectal carcinogenesis. Genes Chromosomes Cancer 2007;46:10-26.
7. Kwong KY, Bloom GC, Yang I, et al. Synchronous global assessment of gene and protein expression in colorectal cancer progression. Genomics 2005;86:142-58.
8. Lin YM, Furukawa Y, Tsunoda T, Yue CT, Yang KC, Nakamura Y. Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas. Oncogene 2002;21:4120-8.
9. Cardoso J, Boer J, Morreau H, Fodde R. Expression and genomic profiling of colorectal cancer. Biochim Biophys Acta 2007;1775:103-7.
10. Sagynaliev E, Steinert R, Nestler G, Lippert H, Knoch M, Reymond MA. Web-based data warehouse on gene expression in human colorectal cancer. Proteomics 2005;5:3066-78.
11. Siddiqui AS, Delaney AD, Schnerch A, Griffith OL, Jones SJ, Marra MA. Sequence biases in large scale gene expression profiling data. Nucleic Acids Res 2006;34:e83.
12. Griffith OL, Melck A, Jones SJM, Wiseman SM. Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. J Clin Oncol 2006;24:5043-51.
13. Maglott D, Ostell J, Pruitt KD, Tatusova T. Entrez Gene: gene-centered information at NCBI. Nucleic Acids Res 2007;35:D26-31.
14. Alibes A, Yankilevich P, Canada A, Diaz-Uriarte R. IDconverter and IDClight: conversion and annotation of gene and protein IDs. BMC Bioinformatics 2007;8:9.
15. Boon K, Osorio EC, Greenhut SF, et al. An anatomy of normal and malignant gene expression. Proc Natl Acad Sci U S A 2002;99:11287-92.
16. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007;9:166-80.
17. Notterman DA, Alon U, Sierk AJ, Levine AJ. Transcriptional gene expression profiles of colorectal adenoma, adenocarcinoma, and normal tissue examined by olignucleotide arrays. Cancer Res 2001;61:3124-30.
18. Zou TT, Selaru FM, Xu Y, et al. Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon. Oncogene 2002;21:4855-62.
19. Buckhaults P, Rago C, St. Croix B, et al. Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Res 2001;61:6996-7001.
20. Croner RS, Foertsch T, Brueckl WM, et al. Common denominator genes that distinguish colorectal carcinoma from normal mucosa. Int J Colorectal Dis 2005;20:353-62.
21. Agrawal D, Chen T, Irby R, et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002;94:513-21.
22. Kim H, Nam SW, Rhee H, et al. Different gene expression profiles between microsatellite instability-high and microsatellite stable colorectal carcinomas. Oncogene 2004;23:6219-25.
23. Bekku S, Mochizuki H, Yamamoto T, Ureno H, Takayama E, Tadakuma T. Expression of carbonic anhydrase I or II and correlation to clinical aspects of colorectal cancer. Hepatogastroenterology 2000;47:998-1001.
24. Yokoyama S, Shatney CH, Mochizuki H, et al. The potential role of fecal carbonic anhydrase II in screening for colorectal cancer. Am Surg 1997;63:243-6.
25. Kivela AJ, Saarnio J, Karttunen TJ, et al. Differential expression of cytoplasmic carbonic anhydrases, CA I and II, and membrane-associated isozymes, CAIX and XII, normal mucosa of large intestine and in colorectal tumors. Dig Dis Sci 2001;46:2179-86.
26. Skonier J, Neubauer M, Madisen L, Bennett K, Plowman GD, Purchio AF. cDNA cloning and sequence analysis of βig-h3, a novel gene induced in a human adenocarcinoma cell line after treatment with transforming growth factor-h. DNA Cell Biol 1992;11:511-22.
27. Schneider D, Kleeff J, Berberat PO, et al. Induction and expression of βig-h3 in pancreatic cancer cells. Biochim Biophys Acta 2002;1588:1-6.
28. LeBaron RG, Bezverkov KI, Zimber MP, Pavelec R, Skonier J, Purchio AF. βIG-H3, a novel secretory protein inducible by transforming growth factor-β, is present in normal skin and promotes the adhesion and spreading of dermal fibroblasts in vitro. J Invest Dermatol 1995;104:844-9.
29. Skonier J, Bennett K, Rothwell V, et al. hig-h3: a transforming growth factor-β-responsive gene encoding a secreted protein that inhibits cell attachment in vitro and suppresses the growth of CHO cells in nude mice. DNA Cell Biol 1994;13:571-84.
30. Akyerli CB, Beksac M, Holko M, et al. Expression of IFITM1 in chronic myeloid leukemia patients. Leuk Res 2005;29:283-6.
31. Yang Y, Lee JH, Kim KY, et al. The interferon-inducible 9-27 gene modulates the susceptibility to natural killer cells and the invasiveness of gastric cancer cells. Cancer Lett 2005;221:191-200.
32. Andreu P, Colnot S, Godard C, et al. Identification of the IFITM family as a new molecular marker in human colorectal tumors. Cancer Res 2006;66:1949-55.
33. de Marco MC, Kremer L, Albar JP, et al. BENE, a novel raft-associated protein of the MAL proteolipid family, interacts with caveolin-1 in human endothelial-like ECV304 cells. J Biol Chem 2001;276:23009-17.
34. Nittka S, Gunther J, Ebisch C, Erbersdobler A, Neumaier M. The human tumor suppressor CEACAM1 modulates apoptosis and is implicated in early colorectal tumorigenesis. Oncogene 2004;23:9306-13.
35. Nosho K, Yamamoto H, Adachi Y, Endo T, Hinoda Y, Imai K. Gene expression profiling of colorectal adenomas and early invasive carcinomas by cDNA array analysis. Br J Cancer 2005;92:1193-200.
36. Jantscheff P, Terracciano L, Lowy A, et al. Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance. J Clin Oncol 2003;21:3638-46.
37. Tai IT, Dai M, Owen DA, Chen LB. Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J Clin Invest 2005;115:1492-502.
38. Lussier C, Sodek J, Beaulieu JF. Expression of SPARC/osteonectin/ BM4O in the human gut: predominance in the stroma of the remodeling distal intestine. J Cell Biochem 2001;81:463-76.
39. Yang E, Kang HJ, Koh KH, Rhee H, Kim NK, Kim H. Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. Int J Cancer 2007;121:567-75.
40. Welsh JB, Sapinoso LM, Kern SG, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A 2003;100:3410-5.
41. Brown DA, Ward RL, Buckhaults P, et al. MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 2003;9:2642-50.
42. Vita M, Henriksson M. The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 2006;16:319-30.
43. Xie D, Sham JS, Zeng WF, et al. Heterogeneous expression and association of β-catenin, p16, and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. Int J Cancer 2003;107:896-902.
44. Bondi J, Bukholm G, Nesland JM, Bukholm IR. Expression of nonmembranous β-catenin and γ-catenin, c-Myc and cyclin D1 in relation to patient outcome in human colon adenocarcinomas. APMIS 2004;112:49-56.
45. Galamb O, Sipos F, Dinya E, Spisak S, Tulassay Z, Molnar B. mRNA expression, functional profiling and multivariate classification of colon biopsy specimen by cDNA overall glass microarray. World J Gastroenterol 2006;12:6998-7006.
46. Wang JY, Yeh CS, Tzou WS, et al. Analysis of progressively overexpressed genes in tumorigenesis of colorectal cancers using cDNA microarray. Oncol Rep 2005;14:65-72.
47. Kwon HC, Kim SH, Roh MS, et al. Gene expression profiling in lymph node-positive and lymph node-negative colorectal cancer. Dis Colon Rectum 2004;47:141-52.
48. Bertucci F, Salas S, Eysteries S, et al. Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 2004;23:1377-91.
49. Ohmachi T, Tanaka F, Mimori K, Inoue H, Yanaga K, Mori M. Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res 2006;12:3057-63.
50. Mori D, Nakafusa Y, Miyazaki K, Tokunaga O. Differential expression of Janus kinase 3 (JAK3), matrix metalloproteinase 13 (MMP13), heat shock protein 60 (HSP60), and mouse double minute 2 (MDM2) in human colorectal cancer progression using human cancer cDNA microarrays. Pathol Res Pract 2005;2001:777-89.
51. Koehler A, Bataille F, Schmid C, et al. Gene expression profiling of colorectal cancer and metastases divides tumours according to their clinicopathological stage. J Pathol 2004;204:65-74.
52. Ichikawa Y, Ishikawa T, Takahashi S, et al. Identification of genes regulating colorectal carcinogenesis by using the algorithm for diagnosing malignant state method. Biochem Biophys Res Commun 2002;296:497-506.
53. Jansova E, Koutna I, Krontorad P, et al. Comparative transcriptome maps: a new approach to the diagnosis of colorectal carcinoma patients using cDNA microarrays. Clin Genet 2006;69:218-27.
54. Grade M, Hormann P, Becker S, et al. Gene expression profiling reveals a massive, aneuploidy-dependent transcriptional deregulation and distinct differences between lymph node-negative and lymph node-positive colon carcinomas. Cancer Res 2007;67:41-56.
55. Bianchini M, Levy E, Zucchini C, et al. Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa. Int J Oncol 2006;29:83-94.
56. Sugiyama Y, Farrow B, Murillo C, et al. Analysis of differential gene expression patterns in colon cancer and cancer stroma using microdissected tissues. Gastroenterology 2005;128:480-6.
57. Kitahara O, Furukawa Y, Tanaka T, et al. Alterations of gene expression during colorectal carcinogenesis revealed by cDNA microarrays after laser-capture microdissection of tumor tissues and normal epithelia. Cancer Res 2001;61:3544-9.
58. Williams NS, Gaynor RB, Scoggin S, et al. Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 2003;9:931-46.
59. Takemasa I, Higuchi H, Yamamoto H, et al. Construction of preferential cDNA microarray specialized for human colorectal carcinoma: molecular sketch of colorectal cancer. Biochem Biophys Res Commun 2001;285:1244-9.
60. Lechner S, Muller-Ladner U, Renke B, Scholmerich J, Ruschoff J, Kullmann F. Gene expression pattern of laser microdissected colonic crypts of adenomas with low grade dysplasia. Gut 2003;52:1148-53.
61. Volp K, Brezniceanu ML, Bosser S, et al. Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas. Gut 2006;55:234-42.
62. Shibao K, Takano H, Nakayama Y, et al. Enhanced coexpression of YB-1 and DNA topoisomerase IIa genes in human colorectal carcinomas. Int J Cancer 1999;83:732-7.
63. Takahashi Y, Ishii Y, Nishida Y, et al. Detection of aberrations of ubiquitin-conjugating enzyme E2C gene (UBE2C) in advanced colon cancer with liver metastases by DNA microarray and two-color FISH. Cancer Genet Cytogenet 2006;168:30-5.
64. Hardy RG, Tselepis C, Hoyland J, et al. Aberrant P-cadherin expression is an early event in hyperplastic and dysplastic transformation in the colon. Gut 2002;50:513-9.
65. Wildi S, Kleeff J, Maruyama H, Maurer CA, Buchler MW, Korc M. Overexpression of activin A in stage IV colorectal cancer. Gut 2001;49:409-17.
66. Madoz-Gurpide J, Lopez-Serra P, Martinez-Torrecuadrada JL, Sanchez L, Lombardia L, Casal JI. Proteomics-based validation of genomic data. Mol Cell Proteomics 2006;5:1471-83.
67. Ushigome M, Ubagai T, Fukuda H, et al. Up-regulation of hnRNP A1 gene in sporadic human colorectal cancers. Int J Oncol 2005;26:635-40.
68. Takahashi K, Sasano H, Fukushima K, et al. 11β-Hydroxysteroid dehydrogenase type II in human colon: a new marker of fetal development and differentiation in neoplasms. Anticancer Res 1998;18:3381-8.
69. Balasubramani M, Day BW, Schoen RE, Getzenberg RH. Altered expression and localization of creatine kinase B, heterogeneous nuclear ribonucleoprotein F, and high mobility group box 1 protein in the nuclear matrix associated with colon cancer. Cancer Res 2006;66:763-9.
70. Chen X, Halberg RB, Ehrhardt WM, Torrealba J, Dove WF. Clusterin as a biomarker in murine and human intestinal neoplasia. Proc Natl Acad Sci U S A 2003;100:9530-5.
71. Kim H, Kang HJ, You KT, et al. Suppression of human seleniumbinding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival. Proteomics 2006;6:3466-76.